GM103 injection for advanced solid tumors that can't be removed
Part of Cancer, Digestive system, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a solid tumor that is advanced, cannot be surgically removed, and has not responded to other treatments or has spread to other parts of the body.
- At least one tumor must be reachable for direct injection with a needle, and you must agree to have tumor samples (biopsies) taken if needed.
- You must be able to get CT or MRI scans to measure your tumors.
- You must be in fairly good health, able to care for yourself (ECOG 0-1), and have a life expectancy of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
This trial tests a new drug called ABL103 combined with pembrolizumab (immunotherapy) and with or without a chemotherapy drug called taxane. It is for people with advanced or metastatic solid tumors that have stopped responding to standard treatments or cannot tolerate them.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This trial tests an injection called NRG-103 given directly into the cavity where a recurrent brain tumor was removed. It is for people with glioblastoma that has come back and who have already had standard treatments.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.